Clinical Trials on Stage I Intraocular Melanoma

Total 1362 results

National Cancer Institute (NCI)

Terminated

A Phase II Study of UCN-01 in Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

BMS-247550 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Metastatic Malignant Neoplasm in Lymph Node

United States
Abramson Cancer Center of the University of Pennsylvania

Terminated

Early FDG PET in Melanoma

Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

United States
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
Philogen S.p.A.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)

Melanoma Stage IV | Melanoma Stage III

United States
Fudan University

Recruiting

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

China
Roswell Park Cancer Institute

Recruiting

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7

United States
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study (ABSIDE)

Malignant Melanoma of Skin Stage III | Malignant Melanoma of Skin Stage IV

Italy
Yong Chen

Not yet recruiting

The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma

Melanoma Stage III

China
Abramson Cancer Center at Penn Medicine

Recruiting

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

Melanoma | Melanoma Stage III

United States
Bristol-Myers Squibb

Completed

Interferon Toxicities in Melanoma Treatment (ITMT)

Stage III Melanoma
Abbott
Biogen

Terminated

A Study of Volociximab in Metastatic Melanoma

Stage IV Melanoma

United States
Philogen S.p.A.

Recruiting

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (NeoDREAM)

Melanoma Stage IIIB/C

Spain, United States, Switzerland
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
Philogen S.p.A.

Active, not recruiting

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Metastatic Melanoma Stage IV

Italy, Germany
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
University Hospital Tuebingen

Unknown

Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI

Malignant Melanoma Stage IV

Germany
University of Washington
National Cancer Institute (NCI)

Terminated

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Biocad

Recruiting

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (NEO-MIMAJOR)

Melanoma (Skin) | Melanoma Stage III

Russian Federation, Belarus
Mayo Clinic
National Cancer Institute (NCI)

Completed

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
M.D. Anderson Cancer Center

Recruiting

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)

Stage III Skin Melanoma

Netherlands
Centre Hospitalier Universitaire de Nice

Completed

Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy (AMMAM)

Metastatic (Stage IV) Melanoma

France
Baylor Research Institute

Terminated

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Malignant Melanoma Stage IV

United States
Saint John's Cancer Institute
Melanoma Research Alliance

Terminated

Stage IV Surgery Versus Best Medical Therapy (STG4SURG)

Stage IV Resectable Melanoma

United States, Australia, Israel, Italy, Netherlands
Vastra Gotaland Region

Withdrawn

Surgery of Melanoma Metastases After Systemic Therapy (SUMMIST)

Melanoma | Surgery | Metastatic Melanoma | Melanoma Stage IV

Sweden
National Cancer Institute (NCI)

Completed

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Dermatologic Cooperative Oncology Group

Unknown

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Therapy | Adjuvant | Stage III Malignant Melanoma | Interferon Alpha

Germany
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Melanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic Melanoma

United States
Erasmus Medical Center

Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Immunotherapy | Melanoma Stage IV | Melanoma Stage III | Toxicity, Drug

Netherlands
Ohio State University Comprehensive Cancer Center

Completed

The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients

Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Daiichi Sankyo, Inc.
Plexxikon

Terminated

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

V600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

United States, Germany, France
Sheba Medical Center

Recruiting

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Malignant Melanoma Stage IV

Israel
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote-695)

Stage III/IV Melanoma

United States, Australia, Canada, Italy, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Completed

Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

Stage IV Skin Melanoma

United States
Inova Health Care Services
Genentech, Inc.

Withdrawn

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Stage IIIB-C Melanoma

United States
Grupo Español Multidisciplinar de Melanoma

Completed

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma (BRAFV600)

Stage IV Skin Melanoma

Spain
Baylor Research Institute

Completed

Combined Modality Treatment for Patients With Stage IV Melanoma

Malignant Melanoma Stage IV

United States

Clinical Trials on Stage I Intraocular Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations